Abstract

Disclosed herein are compounds that act as inhibitors of the serine protease HTRA1, compositions comprising the compounds, and uses of the compounds, e.g., in treatment of HTRA1 associated disorders, including age-related macular degeneration.

IPC Classes  ?

• C07K 5/08 - Tripeptides
• A61K 38/06 - Tripeptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein, are peptides that bind coagulation factor XII (FXII). Also described herein, are methods of administering compounds comprising peptides that bind coagulation FXII to subjects for the treatment of cancer-associated thrombosis, sickle cell disease associated with vaso-occlusive crisis or vascular thrombosis, colon cancer, glioblastoma multiforme, organ fibrosis, Alzheimer's disease, and autoimmune encephalitis.

Abstract

Compositions and methods are provided for modulating, targeting and tracking lymphocyte localization associated with the chemokine CXCL17 and its receptor, identified as GPR25. It is shown herein that GPR25 is a chemoattractant receptor that binds to its ligand chemokine CXCL17, which mediates lymphocyte localization to the airways and non-intestinal mucosal tissues.

Abstract

Provided herein are compositions and methods for diagnosing and treating Parkinson's Disease by the use of one or more of protein biomarkers, e.g., protein expression profile or ratio thereof, from olfactory mucus sample of a subject which is characteristic of PD.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relate to a method. The method includes accessing segmented digitized pathology imaging data from a cancer patient. The segmented digitized pathology imaging data identifies segmented nuclei, segmented mitosis, and segmented tubule regions. A plurality of nuclear features are extracted using the segmented nuclei. A plurality of mitosis features are extracted using the segmented mitosis. A plurality of tubule features are extracted using the segmented tubule regions. A risk score is generated by operating a machine learning model on the plurality of nuclear features, the plurality of mitosis features, and the plurality of tubule features. The risk score correlates to a risk of recurrence of cancer for the cancer patient.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Systems and methods for forming a microfluidic device are disclosed. Microfluidic channels are formed into a substrate. The substrate can be formed into a roll to define a plurality of layers and bonded to itself. The substrate can be at least partly positioned within a housing.

IPC Classes  ?

• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• A61M 1/16 - Dialysis systems; Artificial kidneys; Blood oxygenators with membranes
• B01D 63/10 - Spiral-wound membrane modules
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only

Abstract

Disclosed are method of producing IL-4 exposed M2 macrophage exosomes comprising culturing macrophage or macrophage precursor cells with IL-4 in culture media, and isolating exosomes from the culture media, wherein the isolated exosomes are IL-4 exposed M2 macrophage exosomes enriched with miR-21, miR-99a, miR-146b and miR378a. Disclosed are methods of reprogramming macrophages and/or adipocytes comprising exposing the macrophages and/or adipocytes to IL-4 exposed M2 macrophage exosomes, wherein immune and/or metabolic properties are altered in the macrophages and/or adipocytes. Methods of treating with IL-4 exposed M2 macrophage exosomes.

IPC Classes  ?

• C12N 5/0786 - Monocytes; Macrophages

Abstract

Disclosed herein are compositions and methods for identifying a subject at risk for developing heart failure (HF), heart failure with preserved ejection fraction (HFpEF), or heart failure with reduced ejection fraction (HFrEF). Described herein are also methods of treating subjects identified at risk for developing HF, HFpEF, or heart failure with reduced ejection fraction HFrEF.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

A bacteriophage preparation generally includes a preparation of a heterogeneous bacteriophages obtained from a fermentative process. The bacteriophage preparation may be formulated into a pharmaceutic composition. The bacteriophage preparation may be used to treat dysbiosis by administering the bacteriophage preparation to a subject having, or at risk of having, dysbiosis. The bacteriophage preparation may be used to prepare or prime the gut environment of a healthy subject prior to administering a source of bacteria to the subject.

IPC Classes  ?

• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Methods of treating neuroinflammation in a subject by administering to the subject an agent that inhibits activation of coagulation factor XI (FXI), inhibits the activity of activated FXI (FXIa), or reduces expression of FXI are described. The agent that inhibits activation of FXI can be a monoclonal antibody specific for FXI, such as a monoclonal antibody having the complementarity determining region (CDR) sequences of anti-FXI antibody 14E11. Small molecule inhibitors and antisense compounds directed to FXI or FXIa are also contemplated as agents that inhibit activity of FXIa or reduce expression of FXI. The neuroinflammation in the subject can be associated with any one of a number of different diseases or disorders, such as an autoimmune disease of the central nervous system (CNS) or a neurodegenerative disease.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein, are methods of detecting multiple sclerosis in a subject by measuring relative abundances of multiple oral microbiota in sample. Also, disclosed herein are methods of treatment and prophylaxis of MS.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Methods and systems are described for enhancing user interaction with assistive technology. An input associated with a message may be received from an assistive communication device. A next likely input associated with the message may be determined. The input associated with the message and the next likely input associated with the message may be sent to a user device via a secure communication session. Output of the input associated with the message and output of a prompt to query a user of the assistive communication device of the accuracy of the next likely input associated with the message may be caused via an interface of the user device. An indication that the next likely input associated with the message is accurate may be received via the secure communication session. The message may be updated based on the next likely input associated with the message and caused to be output.

IPC Classes  ?

• G06F 40/274 - Converting codes to words; Guess-ahead of partial word inputs
• G06F 40/166 - Editing, e.g. inserting or deleting

Abstract

An optical analysis device for imaging a test sample with a camera including a housing base defining an interior volume, and a light chamber assembly disposed within the interior volume of the housing base. Optionally, the light chamber assembly includes a light tunnel defined by a continuous tube-shaped wall that extends from a first aperture to a second aperture: a light source is disposed both within the interior volume of the housing base and radially-outwardly of the tube-shaped wall of the light chamber. The camera is selectively positionable adjacent the first aperture of the light tunnel and the sample is selectively positionable within the interior volume of the housing base adjacent the second aperture of the light tunnel.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated

Abstract

The present disclosure relates to syringe cartridges containing a predetermined quantity of a first drug (e.g., sodium bicarbonate having a low moisture content) and to syringe systems and kits containing the syringe cartridge. As described herein, the disclosed syringe cartridges, systems, and kits can be useful in, for example, administering a second drug (e.g., a caine such as lidocaine) and/or to reconstitute the first drug. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61M 5/19 - Syringes having more than one chamber
• A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
• A61M 5/31 - Syringes - Details
• A61M 5/34 - Constructions for connecting the needle

Abstract

Disclosed herein are compositions one or more liposomes, and a targeting peptide, wherein the one or more liposomes comprise a transmembrane protein, and wherein the targeting peptide is outside of the liposome. Also disclosed herein are compositions comprising, an osteoclast-derived microvesicle, and a targeting peptide, wherein the osteoclast- derived microvesicle comprises a transmembrane protein, and wherein the targeting peptide is outside the osteoclast-derived microvesicle. The compositions can be used in methods of treating osteoarthritis, post-traumatic osteoarthritis, or skeletal fractures in subjects.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

A composition comprising microparticles or liposomes comprising one or more MEK1/2 inhibitors, and methods of using the composition, are provided.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/18 - Sulfonamides
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/4412 - Non-condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The present disclosure generally relates to compositions and methods for treating cancer, particularly certain treatment resistant cancers. Various aspects include providing a combination of a receptor tyrosine kinase (RTK) inhibitor and an SUMOylation inhibitor for the treatment of cancer. Also described are treatment of cancers resistant or at risk of becoming resistant to RTK inhibition.

IPC Classes  ?

• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of treating a subject with cancer with a recombinant polypeptide including an antigenic peptide covalently linked to a DRα1 domain or portion thereof comprising a glutamine residue at a position corresponding to amino acid 45 of SEQ ID NO: 1 or SEQ ID NO: 2 are provided. In some examples, the subject is resistant to immune checkpoint blockade treatment and/or has a tumor that does not express a BRAF mutation.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C07K 19/00 - Hybrid peptides

Abstract

Colocasia esculentaColocasia esculenta. This protein has been found to have potent anti-metastatic activity against an aggressive malignancy and a higher specific activity than the prior art taro storage protein composition. The invention therefore relates to the protein compositions described herein, pharmaceutical compositions comprising the recombinant proteins, and to methods for treating cancer, for example breast cancer, using the recombinant proteins or pharmaceutical compositions comprising the recombinant proteins.

Abstract

Provided are compositions and methods for lowering plasma LDL-C, increasing plasma HDL-C, and reducing atherosclerosis. The methods include administering to an individual in need miRNA-541-3P or a modified version thereof, or an agent other than the miRNA-541-3P or the modified version thereof that inhibits the function or expression of ZNF101 or CASZ1, or a combination thereof. Performing a method also decreases expression of apoB increases expression of apoA1 is increased.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The present disclosure generally relates to compositions and methods for treating cancer, particularly certain treatment resistant cancers. Aspects include providing a combination of a receptor tyrosine kinase (RTK) inhibitor and an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of cancer. Aspects provide for treatment of cancers resistant or at risk of becoming resistant to RTK inhibition, including those that do would not normally be treated with ALK inhibition.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61P 35/00 - Antineoplastic agents
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The system and methods described herein diagnose the semantic processing capability of a subject by measuring the neural response of the subject to one or more naturalistic speech stimuli. The system measures the subject's temporal response function to the naturalistic speech by computing a statistical comparison between the subject's neural signal and a time series of semantic metric values corresponding to a transcript of the naturalistic speech stimulus. A diagnosis of the subject's semantic processing capability and the progression of the subject's Alzheimer's disease is then made based on an evaluation of the statistical comparison.

IPC Classes  ?

• A61B 5/38 - Acoustic or auditory stimuli
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Disclosed herein are C. difficile surface proteins that can serve as antigens in a vaccine to prevent C. difficile infection. While many trials have been focused on the use of the C. difficile toxins as antigens, the neutralization of toxins does not prevent colonization by the organism.

IPC Classes  ?

• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 31/4164 - 1,3-Diazoles
• A61K 38/14 - Peptides containing saccharide radicals; Derivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/04 - Antibacterial agents

Abstract

In certain embodiments, the present invention provides a recombinant Dengue virus (DENV) envelope (env) protein and compositions and uses of the DENV env proteins.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

In one aspect, the invention relates to synthetic molecules, compositions and pharmaceutical compositions, which are useful for delivering a bioactive moiety to a site of injury. Also disclosed are methods of treating a tendon injury, methods of treating a fracture, methods of treating a bone stress injury, methods of enhancing incorporation of allograft tissues, methods of promoting repair or regeneration of enthesis tissue during or after an orthopedic surgical procedure, and method of treating osteoporosis, osteoarthritis and/or cartilage defects using the disclosed molecules, compositions and pharmaceutical compositions.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 38/18 - Growth factors; Growth regulators
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

Risk of pressure injuries can be assessed by detecting, in a biological sample, a respective level of at least one biomarker associated with pressure injuries. The biological sample can be, for example, whole blood or other bodily fluids. The at least one biomarker can comprise fatty acid binding protein-3 (FABP3) and/or fatty acid binding protein-4 (FABP4). The biomarkers can be detected by reverse transcription loop-mediated isothermal amplification (RT-LAMP) methods. The biomarkers can be detected by a microfluidics-based biochip.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Disclosed are compositions and methods for treating microbial inflammation including its end-stage sepsis and reversing changes in gene expression resulting from microbial inflammation. In one aspect, the compositions and methods disclosed herein can be used to reduce the microbial lode from infected tissues, organs, or systems in a subject.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are cyclic peptides having activity as cell penetrating peptides (CPPs). Disclosed are cyclic cell penetrating peptides (cCPPs) comprising one or more of the cell penetrating peptides disclosed herein. Disclosed are cCPPs comprising a 6-aminohexanoic-spaced oligoarginine. Disclosed are cCPPs comprising the amino acid sequence of CRXRRXRRXRRXRC (SEQ ID NO:1), wherein X is aminohexanoic acid. In some aspects, the cCPP comprises a disulfide bridge. Disclosed are cCPPs comprising the amino acid sequence of RXRRXRRXRRXRC (SEQ ID NO:2), wherein X is aminohexanoic acid. In some aspects, the cCPPs comprise a thioether bridge.

IPC Classes  ?

• C07K 7/54 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents

Abstract

Devices, systems, and methods for removing or dividing valve leaflets, wherein the devices have an elongate shaft and a cutting tool disposed on or near a distal end of the shaft. Certain embodiments include a cutting tool comprising an expandable structure with a cutting element associated with the expandable structure. Other embodiments have a cutting tool that can extend out of an opening in the elongate shaft. Further implementations have a cutting tool that is a laser fiber, an ultrasound emitting tool, or a radiofrequency emitting tool. Some specific embodiments have a first expandable structure disposed at or near a distal end of the elongate shaft, and a second expandable structure disposed on the elongate shaft proximally of the first expandable structure, the second expandable structure comprising at least one distal projection, wherein the at least one distal projection comprises a cutting tool. Other implementations have a cutting tool comprising first and second jaw arms and first and second blades coupled to the first and second jaw arms, respectively.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
• A61B 17/32 - Surgical cutting instruments
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/24 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Hand-pieces therefor with a catheter

Abstract

Disclosed herein are fully human anti-streptolysin O antibodies useful for treating necrotizing soft tissue infections in a subject. Also disclosed herein are methods of inhibiting or preventing streptolysin O-induced RBC-hemolysis and preventing or inhibiting cytotoxicity in epithelial cells by administering to a subject an effective amount of the anti-streptolysin O antibodies.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents

Abstract

The present application provides pharmaceutical compositions and methods for treating diseases or disorders. The pharmaceutical composition comprises N-methyl-D-aspartate receptor modulator and μ-opioid receptor modulator. The present application also discloses formulations, dosing and administration routes for the pharmaceutical composition. Diseases can be treated by the pharmaceutical composition are also described.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/24 - Antidepressants
• A61P 25/32 - Alcohol-abuse

Abstract

Compositions and formulations containing synthetic M13 analogs are disclosed. The M13 analogs and formulations have anti-inflammatory and antiviral properties, and are suitable for treating multiple types of inflammation and viral infections. Methods of treating, or reducing the risk of developing, one or more symptoms of a viral infection or a disease associated with a viral infection or disease associated with a viral infection in a subject. The methods include administering to the subject a therapeutically effective amount of the pharmaceutical formulation containing one or more synthetic M13 analogs. Also provided are methods of reducing an inflammatory response associated with a viral infection in a subject, by administering to the subject, a therapeutically effective amount of a pharmaceutical formulation containing M13 analogs.

IPC Classes  ?

• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
• C07K 5/093 - Tripeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn

Abstract

Disclosed herein are antibodies that bind to aggregated tau/RNA complexes. Also disclosed herein are methods for treating a taupathy, dementia, ocular pharyngeal muscular dystrophy, or inhibiting microtubule polymerization with antibodies that bind to aggregated tau/RNA complexes.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A headstone socket preserver for insertion in the ground adjacent to a burial site. The headstone socket preserver has a body comprising a top surface, a bottom surface spaced from the top surface along a first axis, and at least one peripheral surface extending between the top surface and the bottom surface. The body can have a decreasing width dimension, measured along a second axis that is perpendicular to the first axis, between the top surface and the bottom surface.

IPC Classes  ?

• E04H 13/00 - Monuments; Tombs; Burial vaults; Columbaria

Abstract

The present disclosure is concerned with substituted thiochromenothiazole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of neurodegenerative disorders associated with dysregulation of MSUT2 signaling such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), motor neuron disease, ataxia, progressive supranuclear palsy (PSP), multiple system atrophy, corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Pick's disease (PiD), dementia, Huntington's disease (HD), primary age-related tauopathy (PART), and aging-related tau astrogliopathy (ARTAG). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07C 317/14 - Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 277/40 - Unsubstituted amino or imino radicals
• C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 513/04 - Ortho-condensed systems
• C07D 513/10 - Spiro-condensed systems
• C07D 513/14 - Ortho-condensed systems

Abstract

Technologies are provided for implementing an interpretation bias modification (IBM) therapy using a mobile device. Some embodiments include a computing device that can initiate a session for interpretation bias modification (IBM) therapy, and can present, as part of the session, a statement describing an ambiguous anger-provoking situation. The computing device also can present, as part of the session, a second statement that comprises a non-threatening interpretation of such situation. That interpretation can be presented in natural language and missing at least one character. The computing device also can receive input defining one or more characters, and can determine that the one or more characters correspond to the at least one character missing in that interpretation. The computing device can then present, as part of the session, a comprehension question corresponding to the non-threatening interpretation, and can prompt selection of an answer to the comprehension question to reinforce the non-threatening interpretation.

IPC Classes  ?

• A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Abstract

A wheelchair having a frame, a footplate that is coupled to the frame and movable relative to the frame about and between a lowered position and a raised position, and a lever that permits actuation of the footplate about and between the lowered position and the raised position. Also disclosed is a wheelchair having a pair of drive wheels, at least one motor, wherein each motor of the at least one motor coupled to a respective drive wheel of the pair of drive wheels, at least one sensor. A controller is in communication with the at least one sensor and each motor of the at least one motor. The controller is configured to control operation of the motor based on input from the at least one sensor.

IPC Classes  ?

• A61G 5/08 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs foldable

Abstract

A system and method for repairing a damaged peripheral nerve is provided. A coupler includes a stabilizing assembly applied to a distal end of a damaged area of the nerve and applied to a proximal end of the damaged area, the coupler adapted so that the proximal end and the distal end are maintained in a stabile abutting relationship in which nerve repair can occur. A chamber is placed in proximity to the damaged area, having a therapeutic agent. Illustratively, the distal end and the proximal end are severed from each other. The coupler can define one of (a) coupler halves that surround the proximal end and the distal end and allow fixing members to be applied to the proximal end and the distal end and (b) cuffs that engage, and are fixed to, each of the proximal end and the distal end and are engaged by overlying coupler halves.

IPC Classes  ?

• A61B 17/11 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for performing anastomosis; Buttons for anastomosis
• A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets

Abstract

The invention generally relates to methods of treating spasticity and/or neuropathic pain using known romidepsin and pharmaceutical compositions comprising same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 38/15 - Depsipeptides; Derivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

IPC Classes  ?

• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61P 31/04 - Antibacterial agents
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Described herein are pyrvinium and its derivatives for reprogramming a pre-cancerous mucosa to a non-cancerous state. Further described herein are pyrvinium and its derivatives for reducing the risk of cancer development in a living organism containing a metaplastic cell or a dysplastic cell.

IPC Classes  ?

• A61K 31/4425 - Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/24 - Antidepressants

Abstract

Disclosed are methods of decreasing cachexia in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of decreasing bone destruction in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of ameliorating one or more symptoms or side effects of breast or prostate cancer in a breast or prostate cancer patient comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof. Disclosed are methods of treating osteoporosis in a subject comprising administering to the subject a therapeutically effective amount of bPTH7-34DD or variant thereof.

IPC Classes  ?

• A61K 38/29 - Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Systems and methods are provided for a gut microbiome signature for cancers, including prostate cancer (PCa), using a prostate specific antigen (PSA)-independent, gut microbiome-based PCa biomarker, which can be used for diagnosis, suitability' for screening, treatment decisions and as part of a treatment method.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure is concerned with methods of making hydroxy derivatives of vitamin D3, compounds useful as intermediates in the preparation of the hydroxy derivatives, and methods of making the intermediates. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• C07C 35/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
• C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups

Abstract

A portion of a catheter is positionable within a heart having a left atrium, an aorta, and a septum. The catheter includes an elongate body having a first portion that is configured to be positioned within a left atrium and a second portion that is distal of the first portion and configured to be positioned in the aorta when the first portion is positioned within the left atrium. Each of the first portion and the second portion defining at least one opening extending from an outer surface to an inner surface of the elongate body. An impeller is configured to effect blood flow through the elongate body from the first portion to the second portion. First, second, and third anchors secure the catheter in position within the heart.

IPC Classes  ?

• A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps
• A61M 60/139 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting inside the aorta, e.g. intra-aortic balloon pumps
• A61M 60/165 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart
• A61M 60/857 - Implantable blood tubes
• A61M 60/865 - Devices for guiding or inserting pumps or pumping devices into the patient’s body
• A61M 60/867 - Devices for guiding or inserting pumps or pumping devices into the patient’s body using position detection during deployment, e.g. for blood pumps mounted on and driven through a catheter
• A61M 60/878 - Electrical connections within the patient’s body
• A61M 60/242 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps with the outlet substantially perpendicular to the axis of rotation

Abstract

A portion of a catheter is positionable within a heart having a left atrium, an aorta, and a septum. The catheter includes an elongate body having a first portion that is configured to be positioned within a left atrium and a second portion that is distal of the first portion and configured to be positioned in the aorta when the first portion is positioned within the left atrium. Each of the first portion and the second portion defining at least one opening extending from an outer surface to an inner surface of the elongate body. An impeller is configured to effect blood flow through the elongate body from the first portion to the second portion. First, second, and third anchors secure the catheter in position within the heart.

IPC Classes  ?

• A61M 60/13 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel by means of a catheter allowing explantation, e.g. catheter pumps temporarily introduced via the vascular system
• A61M 60/165 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart
• A61M 60/237 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller the blood flow through the rotating member having mainly axial components, e.g. axial flow pumps
• A61M 60/414 - Blood pumps; Devices for mechanical circulatory actuation; Balloon pumps for circulatory assistance - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being mechanical, e.g. transmitted by a shaft or cable generated by an electromotor transmitted by a rotating cable, e.g. for blood pumps mounted on a catheter
• A61M 60/508 - Electronic control means, e.g. for feedback regulation
• A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body
• A61M 60/867 - Devices for guiding or inserting pumps or pumping devices into the patient’s body using position detection during deployment, e.g. for blood pumps mounted on and driven through a catheter
• A61M 60/873 - Energy supply devices; Converters therefor specially adapted for wireless or transcutaneous energy transfer [TET], e.g. inductive charging

Abstract

Provided herein are halogenated cholesterol analogues, including methods of making and using the same. Also provided are methods of making radiolabeled cholesterol analogues including admixing an epoxide with a fluorine-18 source under conditions to form a radiofluorinated cholesterol analogue.

IPC Classes  ?

• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C07J 21/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, having an oxygen-containing hetero ring spiro-condensed with the cyclopenta[a]hydrophenanthrene skeleton

Abstract

Static goniometer gages having no moving parts are provided in a set of static goniometer gages to permit measurements of angles over a range of angles. Static goniometers in the set having lobes subtending different angles are used to measure joint range of motion in flexion, extension, abduction and adduction and track changes in joint range of motion in response to occupational therapy.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof

Abstract

The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.

IPC Classes  ?

• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes

Abstract

A control wand for use with an imaging system having a processing unit including a body portion with a front end, a rear end, and an outer surface extending there between, and the body portion is configured to be grasped by a user. A light source assembly is disposed on or within the body portion and includes a first light source that is configured to project a first light beam axially beyond the front end of the body portion to provide a visual indication of an orientation of the control wand.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

In one aspect, the invention relates to synthetic medin peptides, derivatives thereof, and related peptides, which are useful as therapeutic agents for disrupting medin toxicity; synthetic methods of making the peptides; pharmaceutical compositions comprising the peptides, and methods of treating, reducing or preventing vascular dy sfunction, cognitive dysfunction, neurodegeneration, neurovascular pathyology, coronary artery disease and/or ischemic heart disease using the disclosed synthetic medin peptides and compositions thereof.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided are therapeutic methods for treating a patient with lymphedema, or for prophylactically treating an individual susceptible to lymphedema, by blocking P-selectin activity.

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

Compositions and methods are provided for diagnosis and treatment of individuals having multiple sclerosis (MS) or MS spectrum disorders. It is shown herein that EBV-transformed B cells, and particularly plasmablasts, are present in human MS spinal fluid. These cells produce antibodies. e.g. IgG antibodies, that selectively bind to EBV EBNA-1 sequences, including without limitation residues 386-405, and cross-react with the myelin protein hepacam/glialcam, including without limitation residues 337-385.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The disclosure relates to compositions including acetaminophen or analogs thereof and CYP2E1 -inhibitors suitable for parenteral or oral administration. Methods of treating cancer in subjects by administering acetaminophen or analogs thereof and CYP2E1 -inhibitors are also included.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 9/08 - Solutions
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The disclosure relates to compositions and methods of treating mild cognitive impairment in a subject. The method also comprises administering to a subject in need of treatment an effective amount of miR-195, miR-195-5p, miR-195-3p, or fragments or variants thereof

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to compositions comprising exosomes isolated from human adipose-derived stem cells and their use in a method of treating or preventing Parkinson's disease in a subject.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 25/16 - Anti-Parkinson drugs

Abstract

In one aspect, the present disclosure relates to an imaging agent comprising a detectable moiety covalently bound or coordinated to a “Moiety A” selected from a peptide, a chelator, or an organic compound comprising a leaving atom or a leaving group that can be substituted with a radioisotope. “Moiety A” is covalently bound to a flexible linker which is further covalently bound to a polypeptide of between 2 and 20 glycine-proline-hydroxyproline repeats. In certain embodiments, the detectable moiety comprises a radioisotope or metal. In another aspect, the disclosure relates to a method of using the imaging agents of the present disclosure to detect collagen turnover in a subject.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/03 - Computerised tomographs
• A61B 6/42 - Arrangements for detecting radiation specially adapted for radiation diagnosis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 51/08 - Peptides, e.g. proteins
• C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof

Abstract

The disclosure relates to human cells and human cell lines comprising a genetic construct, wherein the genetic construct comprises a SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof, and methods of making the human cells and human cell lines. The disclosure also includes methods of identifying an agent that inhibits release of extracellular vesicles, wherein the extracellular vesicles comprise SARS-CoV-2 RNA, wherein the SARS-CoV-2 RNA does not comprise the spike gene, the envelope gene, the membrane gene or a combination thereof.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

Described herein are compositions and methods for treating cancer in a subject. The compositions include selective NF-κB inhibitor inhibitors. The methods include inhibiting the binding of CARP-1 with NEMO.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/282 - Platinum compounds
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Disclosed are novel compounds for treating and preventing schizophrenia, and more generally psychosis, by bioinformatics drug repurposing using novel genes expression biomarkers involved in psychotic symptoms (delusions, hallucinations); methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for psychosis in a subject; and method of using repurposed drugs and natural compounds to prevent and to treat psychosis. Methods are disclosed using a universal approach, in everybody, as well as personalized approaches by gender. The discovery describes compounds for use in everybody (universal), as well as personalized by gender (males, females). Methods for identifying which subjects should be receiving which treatment, using genes expression biomarkers for patient stratification and measuring response to treatment. The disclosure also relates to algorithms. The algorithms combine biomarkers as well as clinical measures for psychosis, to identify subjects who are at risk of psychosis, and to track responses to treatments.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

Provided herein are compositions, methods, kits and systems for treating cells, tissues and subjects to alter age-related biology (e.g., to study or to treat age-related diseases and conditions). In particular, provided herein are compositions, methods, and uses for inhibition or modification of sialic acid or its cognate receptor to restore phagocytosis in aged cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61M 25/00 - Catheters; Hollow probes
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

A deep learning-based system and method is provided that uses a convolutional neural network to rapidly transform in vivo reflectance confocal microscopy (RCM) images of unstained skin into virtually-stained hematoxylin and eosin-like images with microscopic resolution, enabling visualization of epidermis, dermal-epidermal junction, and superficial dermis layers. The network is trained using ex vivo RCM images of excised unstained tissue and microscopic images of the same tissue labeled with acetic acid nuclear contrast staining as the ground truth. The trained neural network can be used to rapidly perform virtual histology of in vivo, label-free RCM images of normal skin structure, basal cell carcinoma and melanocytic nevi with pigmented melanocytes, demonstrating similar histological features of traditional histology from the same excised tissue. The system and method enables more rapid diagnosis of malignant skin neoplasms and reduces invasive skin biopsies.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G06T 7/00 - Image analysis
• G06T 15/08 - Volume rendering

Abstract

Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.

IPC Classes  ?

• C07K 14/60 - Growth hormone-releasing factor (GH-RF) (Somatoliberin)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/25 - Growth hormone-releasing factor [GH-RF] (Somatoliberin)
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents

Abstract

Methods, systems, and apparatuses are described that are configured for an improved R&D process flow that involves peer-to-peer collaborations, linguistics services, peer review of manuscripts and the outcome of which will be stored as digitized medical/clinical library for developing public relations and marketing material for patient education and engagement using blockchain technology. A plurality of digital assets may be stored in a blockchain network. Each digital asset may be associated with a transaction. Each transaction may be associated with one or more peer nodes of a plurality of peer nodes in the blockchain network. The one or more digital assets may be sent based on one or more transactions satisfying a peer node threshold.

IPC Classes  ?

• G06Q 20/38 - Payment architectures, schemes or protocols - Details thereof
• G06Q 20/22 - Payment schemes or models

Abstract

The present disclosure provides methods for decreasing injuries associated with intraoperative hypotension by intravenously administering to a subject a therapeutically effective amount of a fat emulsion, following a period of intraoperative hypotension and after the subject's mean arterial blood pressure has recovered. The disclosure also provides methods for preventing injuries associated with intraoperative hypotension, particularly for surgical candidates that have an increased risk for intraoperative hypotension. Non-limiting examples of injuries contemplated herein include myocardial injury, myocardial infarction, and acute kidney injury.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

IPC Classes  ?

• C07C 233/91 - Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated with carbon atoms of the carboxamide groups bound to acyclic carbon atoms
• C07C 233/90 - Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
• C07D 309/06 - Radicals substituted by oxygen atoms
• C07C 321/20 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• C07D 303/48 - Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• C07C 243/32 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

In various aspects and embodiments, the invention provides a tissue engineered neuromuscular interface comprising: an extracellular matrix core; the extracellular matrix core comprising: a population of neurons at a first end of the extracellular matrix core, the population of neurons having axons extending at least a portion of the way along the extracellular matrix core; wherein the population of neurons is selected from the group consisting of one or more motor neurons, one or more motor neurons co-cultured with one or more sensory neurons, and a co-aggregate comprising one or more motor neurons and one or more sensory neurons.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: The invention provides a method for (a) increasing skeletal muscle mass; (b) reducing skeletal muscle atrophy; (c) increasing muscular strength; (d) promoting muscle growth; (e) decreasing muscle wasting; or (f) increasing strength per unit of muscle mass in an animal identified or having been identified to be in need of one or more of (a)-(f), the method comprising administering to the animal an effective amount of a compound of formula: or a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, thereby accomplishing one or more of (a)-(f).

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/473 - Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

e.ge.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease) or an acute injury to the nervous system in a subject comprising administering to the subject an effective amount of boldine, a boldine analog, or a pharmaceutically-acceptable salt thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• A61K 31/02 - Halogenated hydrocarbons
• A61K 31/33 - Heterocyclic compounds

Abstract

Compositions, methods, and kits are provided for treating inflammatory eye diseases. In particular, methods of treating intraocular inflammation with a semaphorin 7A peptide or peptidomimetic are provided.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

Methods, systems, and/or apparatuses are described for providing electrical stimuli and motorized assistance for leg movement of a user. A quantity of electrical stimuli may be provided to a portion of a paretic leg during the first step of a walking motion. Motorized assistance at a quantity of torque may be provided to the portion of the paretic leg during the first step of the walking motion. Data associated with the paretic leg during the first step of the walking motion may be received. Based on the data, the deviation of the paretic leg, during the first step of the walking motion, from the target configuration for the paretic leg may be determined. The quantity of electrical stimuli during the next step of the walking motion for the paretic leg may be modified.

IPC Classes  ?

• A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/04 - Electrodes
• A61N 1/08 - Arrangements or circuits for monitoring, protecting, controlling or indicating
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

Provided herein are conjugates, systems, compositions, and methods for delivery of active agents to the brain. In particular, conjugates, systems, and compositions comprising ApoA1 and/or ApoA2 and an active agent are provided.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Disclosed herein are antibodies that bind to aggregated tau/RNA complexes. Also disclosed herein are methods for treating a taupathy, dementia, ocular pharyngeal muscular dystrophy, or inhibiting microtubule polymerization with antibodies that bind to aggregated tau/RNA complexes.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 27/02 - Ophthalmic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Instances of a single brain computer interface (BCI) system can be implemented on multiple devices. An active instance can control the associated device. The instances can each communicate with a neural decoding system that can receive neural signals from a user, process the neural signals, and output a command based on the processed neural signals. A device running the active instance of can be in communication with the neural decoding system to receive a command. The device can include a display, a non-transitory memory storing instructions, and a processor to execute the instructions to: run an instance of a control program; and execute the task based on the command.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

Provided herein are living scaffolds for peripheral nerve regeneration, the living scaffolds including tissue engineered nerve grafts (TENGs) programmed to express neurogenic growth factors with temporal and spatial control. Further provided herein are compositions and methods for facilitating nerve regeneration, such as compositions and methods comprising TENGs modified to express a neurotrophic growth factor.

IPC Classes  ?

• A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• C07K 14/475 - Growth factors; Growth regulators
• C12N 15/86 - Viral vectors

Abstract

Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/475 - Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - Platinum; Compounds thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

Abstract

An assembly can be configured to couple to an attachment structure. The assembly can comprise a cup holder having a top opening and defining an interior that is configured to receive and hold at least a portion of a cup. A bracket can be pivotably coupled to the cup holder about a horizontal axis so that the top opening faces upwardly. The bracket can comprise a coupling structure that is configured to couple to an attachment structure.

IPC Classes  ?

• A47G 23/02 - Glass or bottle holders

Abstract

The present invention features compositions and methods for the localization and concentration of various growth factors (e.g., vascular endothelial growth factor (VEGF), or an angiopoietin-1 (ANG1) protein, or an angiopoietin-2 (ANG2) protein) within a scaffold structure. The present invention may also be used to promote the rebuilding of vasculature on de-celled organs (e.g., a kidney) or artificial organs.

IPC Classes  ?

• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 38/18 - Growth factors; Growth regulators
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Disclosed herein are methods of treating or preventing the development of osteoarthritis after a joint injury by administering a CD14 inhibitor capable of neutralizing or blocking CD14, inhibiting CD14 function, inhibiting CD14 production, or a combination thereof. Also disclosed herein are methods of reducing or ameliorating one or more symptoms of osteoarthritis, reducing inflammation, reducing cartilage degradation, or treating or preventing subchondral bone sclerosis in a subject.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C07K 14/745 - Blood coagulation or fibrinolysis factors
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides an encapsulated gas or partial vacuum particle contrast media for use in CT imaging. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water. Exemplary encapsulated gas or partial vacuum particle has a specific gravity between 0.2 and 1.5. In various embodiments, the encapsulated gas or partial vacuum particle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended homogeneously. In an exemplary embodiment, the encapsulated gas or partial vacuum particle comprises 5% or more of the weight of the contrast material formulation. The invention also provides methods for imaging of the abdomen by dual energy CT or spectral CT contemporaneously with the delivery of the encapsulated gas or partial vacuum particle contrast material into the bowel lumen with or without the delivery of a second complementary contrast material into the blood vessels or other body compartments. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues to generate multiple resultant CT images with the contrast medium of the invention subtracted or highlighted.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 6/03 - Computerised tomographs
• A61K 9/10 - Dispersions; Emulsions
• A61K 9/50 - Microcapsules
• A61K 49/04 - X-ray contrast preparations

Abstract

Disclosed herein are compositions and methods for sequencing, analyzing, and utilizing samples such as single samples. Also disclosed herein are compositions and methods for matching together two or more sequences from a sample. Also disclosed herein are compositions and methods for expressing and screening molecules of interest.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to novel bi-specific antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bi-specific antibody molecules capable of inhibiting immune effector cells and their use in diagnosis and/or treatment of various diseases.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present disclosure, in some embodiments, relates to a method. The method includes accessing one or more digitized pathology images of a cell cluster area comprising epithelial cells obtained from a bile duct of a patient having a bile duct stricture. The cell cluster area is segmented to identify segmented nuclei and non-nuclei regions. A plurality of texture features are extracted from the segmented nuclei and the non-nuclei regions. A plurality of nuclear shape features are extracted from the segmented nuclei. The plurality of nuclear shape features and the plurality of texture features are provided to a machine learning model configured to generate a cytological diagnosis of the epithelial cells within the cell cluster area.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 10/02 - Instruments for taking cell samples or for biopsy
• G06T 7/11 - Region-based segmentation
• G06T 7/40 - Analysis of texture
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods, systems, and apparatuses are described for clinical system integration. For example, a computing device may receive a request based on one or more of a plurality of clinical systems. The computing device may retrieve, based on the request, a first plurality of interface components. The first plurality of interface components may be retrieved from each of the plurality of clinical systems in real-time. The computing device may convert the first plurality of interface components to a second plurality of interface components. The second plurality of interface components may correspond to the computing device.

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

Disclosed herein, are methods of determining the amount of Gas palmitoylation in a blood sample using mass spectrometry. Also disclosed herein, are methods of determining the severity of depression in a subject as well as determining the whether a subject will respond to antidepressant therapy by determining the amount of Gas palmitoylation in a blood sample using mass spectrometry. Further disclosed herein are methods of determining the effectiveness of antidepressant agent in a depressed subject by measuring the association of Gas with adenylyl cyclase by fluorescence or by methods for measuring cAMP.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

Abstract

The present invention features methods for characterizing mutational profiles in patients with bladder cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

An apparatus for lifting and moving a patient including a cart assembly with at least one drive wheel assembly secured thereto, a carriage assembly that is rotatably secured to the cart assembly, the carriage assembly including a lift assembly with a support arm, a patient support device operably secured to the support arm, and a counterweight assembly, the counterweight being movable along a longitudinal axis of the carriage assembly.

IPC Classes  ?

• A61G 7/10 - Devices for lifting patients or disabled persons, e.g. special adaptations of hoists thereto

Abstract

A device for measuring pushrim dynamics of a pushrim of a wheel of a wheelchair includes a plurality of beam sensing elements configured to be placed in connection with the pushrim. A sensor system of the device includes one or more sensors in connection with each beam sensing element to measure bending thereof. A modular hub of the device includes a mounting base which includes beam sensing element connectors to attach each of the beam sensing elements thereto to extend radially from the mounting base in a predetermined spaced relation. The modular hub further includes an inner hub flange configured to be removably connected on an inner side of the mounting base and an outer hub flange configured to be removably connected on an outer side of the mounting base. Each of the inner hub flange and the outer hub flange is configured to be operatively connected to the wheel.

IPC Classes  ?

• A61G 5/02 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs propelled by the patient or disabled person
• A61G 5/10 - Parts, details or accessories
• B62M 1/14 - Rider propulsion of wheeled vehicles operated exclusively by hand power

Abstract

A method of treating a subject having, or at risk of having, leaky gut caused by sulfate reducing bacteria generally includes administering to the subject an amount of a Snail inhibitor or an inhibitor of sulfate reducing bacteria effective to reduce ameliorate at least one symptom or clinical sign of leaky gut caused by sulfate reducing bacteria. A method of inhibiting deterioration of cellular junctions in cells contacted with sulfate reducing bacteria generally includes contacting the cells with an amount of Snail inhibitor or an inhibitor of sulfate reducing bacteria effective to reduce the extent to which the sulfate reducing bacteria deteriorate cellular junctions compared to untreated cells.

IPC Classes  ?

• A61K 31/29 - Antimony or bismuth compounds
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61K 33/24 - Heavy metals; Compounds thereof

Abstract

An apparatus having a longitudinal axis and an upper surface for supporting an individual at least partially positioned on a bed or other support structure, such as, for example, a bed within a magnetic resonance imaging (MRI) machine, is disclosed. The individual can have hips, legs and an upper back. The apparatus comprises a bladder that is configured to be positioned beneath the hips of the individual. The bladder has a first end and an opposed second end that is spaced from the first end along the longitudinal axis. The bladder is configured to expand upon receiving air from an air supply in order to elevate the hips of the individual relative to the upper back of the individual. A valve is in fluid communication with the bladder. The valve is configured to selectively allow air from the air supply into the bladder. The apparatus can be nonferrous.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

The presently-disclosed subject matter includes a compound comprising a first monomer, which is allyl-functionalized and crosslinkable, and a second monomer, which is not crosslinkable. In some embodiments the compounds are photocrosslinkable, and in certain embodiments are photo crosslinkable by ultraviolet light. Also provided are shape memory vascular grafts comprised the of present compounds that can transition from a temporary shape to an original shape when heated above a melting temperature of the graft. Still further provided are methods for treating vascular conditions that utilize embodiments of the present grafts.

IPC Classes  ?

• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61F 2/07 - Stent-grafts
• A61F 2/90 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
• A61L 31/04 - Macromolecular materials
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• C08G 63/08 - Lactones or lactides

Abstract

Described herein are dosing regimens and methods of treating multiple sclerosis with an effective amount of an erythropoietin (EPO)-derived peptide to provide sustained therapeutic effects after withdrawal of the EPO-derived peptide. The dosing regimens and methods include a treatment cycle followed by a rest phase, wherein the EPO-derived peptide is not administered during the rest phase.

IPC Classes  ?

• A61K 38/18 - Growth factors; Growth regulators
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

This document relates to methods and materials involved in treating stroke. For example, nanoparticles (e.g., polymer-coated nanoparticles) designed to deliver two or more poly peptides that are normally secreted from mesenchymal stem cells (MSCs; e.g., MSCs of a human less than 33 years of age)) to the brain are provided as well as methods for using such nanoparticles to treat a mammal (e.g., a human) having or having had a stroke.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 9/51 - Nanocapsules
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 38/18 - Growth factors; Growth regulators
• A61K 38/30 - Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Interferon-γ-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.

IPC Classes  ?

• A61K 38/19 - Cytokines; Lymphokines; Interferons
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 35/00 - Antineoplastic agents
• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors

Abstract

The disclosure relates to compositions and methods of treating Gulf War illness or syndrome in a subject. The method comprises administering to a subject in need of treatment an effective amount of a nuclear receptor peroxisome proliferator-activated receptor gamma agonist and a nuclear factor erythroid 2-related factor 2 agonist.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/05 - Phenols
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods for the treatment of condition associated with bromodomain and extraterminal domain (BET) protein activity are disclosed. The methods include administering a therapeutically effective amount of a piperazine BET protein inhibitor or a piperidine BET protein inhibitor to a subject in need thereof. Piperazine BET protein inhibitors, piperidine BET protein inhibitors, and pharmaceutical compositions comprising the BET proteins inhibitors are also described.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention includes anti-single-chain variable fragment (scFv) antibodies or antigen-binding fragments thereof, wherein the scFv is an scFv of a CAR, and uses thereof (e.g., for targeting one or more immunostimulatory cytokines to modified immune cells which express the CAR and/or for activating said CAR-expressing immune cells without affecting cytotoxic potential or inducing exhaustion). The invention includes an antibody-linked cytokine, wherein the antibody is the anti-scFv antibody or antigen-binding fragment, and use thereof in a method of treating cancer. The invention further includes a lipid nanoparticle (LNP) harboring nucleoside-modified RNA(s) encoding at least one immunostimulatory cytokine, wherein the LNP comprises the anti-scFv antibody or antigen-binding fragment linked to the surface of the LNP, and use thereof.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C07K 14/54 - Interleukins (IL)
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

Disclosed are nucleic acid sequences comprising a cardiomyocyte-specific, cardiac stress-induced promoter operably linked to a mitochondrial targeting sequence (MTS) and/or a gene of interest. Disclosed are vectors comprising one or more of the disclosed nucleic acids. Disclosed are methods of using the disclosed nucleic acid sequences or vectors for treating a subject in need thereof. Disclosed are methods of treating pulmonary hypertension (PH) in a subject comprising administering a therapeutically effective amount of a vector to the subject, wherein the vector comprises a nucleic acid sequence comprising a cardiomyocyte-specific, cardiac stress-induced promoter operably linked to a mitochondrial targeting sequence (MTS) and/or a gene that encodes a PH therapeutic, wherein the PH therapeutic is expressed in cardiomyocytes undergoing cardiac stress.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 9/10 - Transferases (2.)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/86 - Viral vectors

Abstract

Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 38/19 - Cytokines; Lymphokines; Interferons
• A61K 38/45 - Transferases (2)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material